Myelodysplastic Syndromes (MDS)

Oral Hypomethylating Agent Regimen Approved for MDS Improves Outpatient Treatment Options

Original Publication Date

August 5, 2020

Article Source

External Web Content

In an interview with Targeted Oncology, Guillermo Garcia-Manero, MD, discussed the FDA’s recent approval of oral decitabine and cedazuridine as treatment of patients with myelodysplastic syndromes and the data that supported this decision. In July 2020, the FDA granted approval…

Letter to the Editor: Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality

Read more about Letter to the Editor: Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality

Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients

Read more about Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients

Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions

Read more about Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions

The anemia anemia: (uh-NEE-mee-uh) A condition in which there is a shortage of red blood cells in the bloodstream. This causes a low red blood cell count.

Chronic fatigue in myelodysplastic syndromes: Looking beyond anemia

Read more about Chronic fatigue in myelodysplastic syndromes: Looking beyond anemia

Chronic fatigue is the most common and severe symptom in myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-

Eat and be healthy: nutritional status in myelodysplastic syndromes

Read more about Eat and be healthy: nutritional status in myelodysplastic syndromes

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

Read more about Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

Tumor protein p53 (TP53) is the most frequently mutated gene in cancer1,2.

Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial

Read more about Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial

Background: The median overall survival of patients with high-risk myelodysplastic syndromes myelodysplastic syndromes:

Kinetics of Pre-Myelodysplastic Syndromes Blood Values Correlate with Disease Risk and Survival

Read more about Kinetics of Pre-Myelodysplastic Syndromes Blood Values Correlate with Disease Risk and Survival

We reviewed pre-diagnosis clinical data of 420 patients with pathologically confirmed myelodysplastic syndromes myelodysplastic syndromes:

TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype

Read more about TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype

Somatic gene mutations are key determinants of outcome in patients with myelodysplastic syndromes myelodysplastic syndromes:

Subscribe to Myelodysplastic Syndromes (MDS)

AAMDSIF Awareness Week